Comparison of platelet aggregation of ticagrelor 180 mg, clopidogrel 600 mg loading dose and prasugrel 60 mg loading dose and correlation of response of platelet aggregation to CYP2C19*2, *3, and *17 single nucleotide polymorphisms in Thai patients who planned undergoing coronary angiography.

Trial Profile

Comparison of platelet aggregation of ticagrelor 180 mg, clopidogrel 600 mg loading dose and prasugrel 60 mg loading dose and correlation of response of platelet aggregation to CYP2C19*2, *3, and *17 single nucleotide polymorphisms in Thai patients who planned undergoing coronary angiography.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs Clopidogrel (Primary) ; Prasugrel (Primary) ; Ticagrelor (Primary)
  • Indications Coronary disorders
  • Focus Pharmacodynamics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 18 Jul 2017 Status changed from recruiting to active, no longer recruiting.
    • 05 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top